ro glp-1 supply tracker Injection Tracker: Weight Loss & Symptom Management (printable PDF) Ro launches the GLP-1 Supply

"Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial." New England Journal of Medicine , 2023

You shouldnt take these medications if you: Are pregnant, breastfeeding, or trying to get pregnant Have a family or personal history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2) Have a known allergy to any ingredients in the medication Have a personal or family history of pancreatitis GLP-1 agonists cost and accessibility While these drugs can be highly effective, they can also be expensive

They are not for human consumption, medical use, veterinary use, therapeutic use, diagnostic use, or clinical application

Retatrutide reduced liver fat by 82% in trials, compared to roughly 55% for tirzepatide (Nature Medicine, 2024)

Liu Z-Z, Duan X-X, Yuan M-C, Yu J, Hu X, Han X, et al

Exercise timing also matters